Moreover, mutations in PI3K and MAPK pathways are common in metastatic CRC and accelerate tumour growth in conjunction with other prevalent mutations in the p53, TGF-β and Wnt signalling pathways [153]. The gene discussed is PIK3CG; the disease is neoplasm.